TABLE 1.

Characteristics of 6 Women with IDC

Patient	Age (y)	Sites of known malignancy at time of 89Zr-pertuzumab administration	Days after 89Zr-pertuzumab administration on which PET/CT imaging was done	Sites of demonstrably 89Zr-pertuzumab–avid disease
1	46	Brain	1, 2, 6, 8	Brain
2	68	Nodal	1, 2, 5, 7	Nodal
3	58	Breast, nodal	1, 2, 6, 7	Breast, nodal
4	69	Liver, bone, chest wall	1, 4, 5, 8	Chest wall
5	38	Brain, lung, nodal, liver	1, 2, 5	Brain, lung, nodal
6	42	Nodal	1, 4, 5, 7	None